Febuxostat in the treatment of chronic gout

2018-02-07
George Nuki

What is the current role of febuxostat in the treatment of chronic gout?

George Nuki: The American guidelines suggest that allopurinol and febuxostat should be equally considered for first-line therapy. The European and British guidelines do not because they take into account the cost-effectiveness and the cost of these. Febuxostat, to put it shortly, has become a generic drug, so things may change in that case. But at the moment the European recommendation is that febuxostat should be used if people cannot be adequately controlled with allopurinol or if they have hypersensitivity problems to it.

See also
  • Screening joint US in patients with asymptomatic hyperuricemia to search for uric acid deposits Should patients with asymptomatic hyperuricemia undergo screening joint ultrasonography to search for uric acid deposits?
  • Tests in patients with suspected GCA What tests should be performed in the case of suspected giant cell arteritis (GCA)? What should we look for in the physical examination, laboratory tests, and imaging studies?
  • Axial SpA: diagnostics, treatment, disease activity Dr Filip Van den Bosch, associate professor of rheumatology at Ghent University, Belgium, reviews the current diagnostic methods, treatment, and activity measurement used in patients with nonradiographic axial spondyloarthritis in a conversation with Dr Mariusz Korkosz.
  • Low-dose colchicine after 12 hours from the onset of gout flare According to the EULAR guidelines, in gout flares colchicine is recommended within 12 hours of the onset of symptoms. Because most patients frequently present after this time, the recommendation concerns self-administration of colchicine and treatment of subsequent flares. Can we use low-dose colchicine if the patient presents after 12 hours from the onset of symptoms? Or should we prefer nonsteroidal anti-inflammatory drugs or steroids?
  • Knee osteoarthritis: When arthroscopy can help In the light of recent studies suggesting limited benefit for arthroscopic surgery in the setting of osteoarthritis, the authors of the review highlight the importance of this intervention in the management of patients with other pathologies involving the knee who may have a concomitant diagnosis of osteoarthritis.
  • Imaging studies in patients with PMR Is it necessary to perform imaging studies looking for vasculitides, such as aortitis, in all patients with polymyalgia rheumatica (PMR)? What imaging studies are recommended?

We would love to hear from you

Comments, mistakes, suggestions?